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Abstract
Generating monoclonal antibodies from single B cells is a valuable tool for characterizing the 
specificity and functional properties of humoral responses. We and others developed protocols that 
have facilitated major advances in our understanding of B cell development, tolerance, and 
effector responses to HIV and influenza. Here, we demonstrate various refinements and 
dramatically reduce the time required to produce recombinant antibodies. Further, we present new 
methods for cloning and isolating antibodies from cells with lower immunoglobulin mRNA levels 
that may be resistant to traditional techniques. Together, these refinements significantly increase 
single-cell antibody expression efficiency and are easily integrated into established and novel 
pipelines.
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Technical Note
Antibodies are the primary mediator of humoral immunity, so they are a recurrent focus of 
scientific inquiry and medical discovery. In recent years, characterization of humoral 
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responses by production of monoclonal antibodies from single cells has enabled rapid 
advances in B cell biology due to the high throughput and efficiency of these methods1–3. 
These include the isolation of large numbers of broadly neutralizing antibodies against 
diverse pathogens like HIV and influenza, which are revolutionizing vaccine and therapeutic 
design. Single cells from a population of interest are isolated using flow cytometry then 
immunoglobulin genes from each cell are cloned into a vector for protein expression. The 
resulting antibodies are used for downstream assays to study their specificity, function, and 
repertoire characteristics.
A popular use for this involves screening panels of monoclonal antibodies, allowing a clonal 
assessment of the specificities present in a population of interest. Antibodies derived from 
plasmablasts, the temporary effector cells that peak 7 days after an immune response, 
present an opportunity to study acute infection and vaccination4,5. Memory B cells give 
access to affinity-matured antibodies, especially those formed during chronic or repeated 
infections6,7. An advantage of this method over traditional serum or hybridoma methods is 
that rare single cells with desirable antibodies can be isolated. Characterization of individual 
monoclonal antibodies yields data on specificity, binding conformation, reactivity breadth 
and potency, and protective capacity. Studies using these methods have shed light on 
potential targets for universal vaccine development and provide benchmarks for evaluating 
future therapeutics.
Here, we show several refinements for single-cell cloning and antibody expression that 
eliminate bottlenecks by replacing various single-sample manipulations with high-
throughput alternatives. For large-scale projects, these changes are easily implemented and 
noticeably increase the pace at which antibodies can be generated. Further, our methods 
enable high-throughput isolation and characterization of antibodies from cells with relatively 
low immunoglobulin expression levels such as naïve or memory B cells. Limitations that are 
inherent to generating antibodies from single cells remain, including cell fragility 
(plasmablasts cannot be frozen and thawed) and the time-consuming nature of sorting cells 
and transfecting individual antibodies. Additionally, the lack of PCR error correcting 
mechanisms necessitate redundancy measures and the occasional redo. Instructions and 
primers for creating both fully human and chimeric (murine variable region and human 
constant region) antibodies are included.
Methods
This section describes the steps that are substantially different from our previously published 
protocol3. A complete protocol, which includes other modifications and quality-of-life 
changes, is included as supplementary material. Table 1 compares the bench time required 
for each step for our old protocol and this new protocol.
We applied this procedure to human plasmablasts isolated seven days after seasonal 
influenza vaccination and pneumococcal vaccination. We validated the cloning efficiency of 
the new protocol (Figure 1a) and confirmed the production of vaccine-specific antibodies by 
ELISA (Figures 1b, 1c).
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Peripheral blood samples were collected in accordance with the University of Chicago 
Institutional Review Board (#09-043-A) and informed consent was obtained from all 
subjects.
cDNA preparation
To prepare template cDNA from lysed cells, a non-specific cDNA synthesis kit is used rather 
than immunoglobulin-specific primers. With specific primers, for each sample plate only one 
of the light chain genes (lambda or kappa) can be reverse transcribed, and antibodies that use 
the other gene are lost. With non-specific primers, both lambda and kappa chain DNA can 
be recovered from the same plate.
Important: use RNase-free precautions.
Direct cDNA synthesis from sorted and lysed cells
This is efficient for most cell types, especially plasmablasts. Non-plasmablast human 
cells may experience slightly diminished PCR efficiency.
Note: Sort cells into 10 µl/well of catch buffer (for ten half-plates: 5 ml RNase-free 
water, 50 µl 1M Tris pH 8.0, 125 µl RNasin; make fresh each time)
1. Create the master mix.
cDNA reaction 1 well
5x Buffer Mix 3 µl
Maxima Enzyme Mix 1.5 µl
5% IGEPAL 1.5 µl
2. Aliquot 6 µl master mix into each well with catch buffer, for a total 
reaction volume of 16 µl. Run the following program. Store plates at 
−20°C.
25°C for 10 min
50°C for 30 min
85°C for 5 min
4°C forever
cDNA synthesis after RNA purification
Purification with SPRI beads removes debris and other contaminants, increasing the 
efficiency of cDNA synthesis and subsequent PCRs8. A variety of murine non-
plasmablast cells amplify very inefficiently; SPRI purification increases the yield of 
naïve cells, small intestinal IgA plasma cells, and colonic IgA plasma cells by 41%, 
17%, and 127% respectively (Figure 2). However, this technique may be useful for all 
plates that have low PCR efficiency.
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Note: Do not sort cells into catch buffer. Instead, use 5 µl/well of TCL buffer and 1% 
beta-mercaptoethanol (vol/vol). Plates can be flash-frozen on dry ice and stored at 
−80°C.
1. Warm RNase-free SPRI beads to room temperature.
2. Add 10 µl nuclease-free water to each sample, then add 33 µl SPRI 
beads to each sample. Cover plate to prevent contamination and 
incubate at room temperature for 10 min.
3. Place the plate on top of the magnetic plate and incubate, covered, 
at room temperature for 5 minutes.
4. Wash the plate 3x with 75 µl 80% EtOH, incubating 30 sec each 
cycle. Upon final aspiration, air dry for 8 min and remove from the 
magnetic plate.
5. Begin cDNA synthesis by resuspending beads in 10 µl/well reverse 
transcription mix #1, and thermocycle.
cDNA reaction #1 1 well
10mM dNTPs 1.25 µl
Oligo d(T)18V 1 µl
Template RNA pellet -
Nuclease-free water to 10 µl
65°C for 5 min
4°C forever
6. Incubate on ice for 1 min, then add reverse transcription mix #2; 
aliquot 10 µl/well and cycle. Store plates at −20°C.
cDNA reaction #2 1 well
5x SuperScript IV RT Buffer 4 µl
100 mM DTT 1 µl
RNaseOUT 0.5 µl
SuperScript IV Reverse Transcriptase 0.25 µl
Nuclease-free water to 10 µl
50°C for 1 hr
80°C for 10 min
4°C forever
Cloning
After cDNA preparation, two rounds of PCR are performed to amplify immunoglobulin 
genes for sequencing. The products of the first round are used as templates in a cloning PCR 
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reaction to generate DNA for insertion into expression vectors. We designed sequence-
specific primers that each contain an overhanging region that overlaps with the proper 
expression vector. To join the insert with the vector, we use Gibson assembly, a rapid 
procedure for assembling DNA fragments with overlapping ends9 (Figure 3). Overall, this 
process is much quicker than the traditional digest-ligation method and slightly more 
reliable, reducing the number of sequences that must be redone (data not shown).
Materials:
QIAquick gel extraction kit (Qiagen, 28706)
FastDigest BshTI (AgeI) (Thermo, FD1464)
FastDigest SalI (Thermo, FD0644)
FastDigest Pfl23II (BsiWI) (Thermo, FD0854)
FastDigest Xho1 (Thermo, FD0694)
FastAP (Thermo, EF0654)
GeneJET Gel Extraction Kit (Thermo, K0692)
Linearize plasmids to prepare expression vectors for assembly
(Vector sequences can be found on NCBI GenBank: accession numbers FJ475055, 
FJ475056 and FJ517647 for heavy, kappa, and lambda, respectively; the vectors are 
available upon request)
1. Reaction setup
Note: 25 ng gel-purified vector is needed per assembly reaction
Vector digest
Plasmid with heavy, kappa, or lambda vector 5 µg
10x FastDigest buffer 5 µl
Chain-specific restriction enzyme 2.5 µl
BshTI (AgeI) 2.5 µl
H2O to 50 µl
Chain-specific restriction enzymes:
Heavy: SalI
Kappa: Pfl23II (BsiWI)
Lambda: Xho1
2. Incubate at 37°C for 15 minutes, then add 2.5 µl FastAP. Repeat.
3. Incubate at 37°C for 10 minutes.
4. Heat-inactivate at 80°C for 10 minutes.
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5. Run on a 1.2% agarose gel (100V for 5 min, then 75V for 75 min) 
and cut bands with the digested vectors from the gel for extraction.
6. Purify by following the protocol outlined in the GeneJET Gel 
Extraction Kit with one exception: elute the final product in 40 µl 
EB.
Perform overlap PCR with Gibson assembly primers
Important: to avoid contamination, avoid contact with the interior of Eppendorf tubes 
and limit airflow over open racks. Wipe pipettes and surfaces with DNA off before 
use.
1. Create a master mix for each combination of 5' and 3' primers (for 
details on choosing primers, refer to the Supplementary Methods). 
The template is the unpurified product of the 1st PCR step. Include 
a template-less negative control for each master mix of primers to 
ensure there is no contamination.
Human cloning PCR 1 well
5' primer (10 µM) 1 µl
3' primer (10 µM) 1 µl
2X Green DreamTaq MasterMix 12.5 µl
Nuclease-free H2O 9 µl
1st PCR product 1.5 µl
Thermocycle:
94°C for 4 min
Repeat 40x:
94°C for 30 sec
58°C for 30 sec
72°C for 45 sec
72°C for 8 min
4°C forever
The above PCR details are optimized for human primers; see the supplementary 
methods for mouse cloning PCR instructions.
2. Run 2 µl PCR product directly on a 1% agarose gel to confirm a 
successful reaction and to check for contamination in the negative 
control wells.
Perform Gibson assembly
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1. Reaction setup (it is not necessary to purify the cloning PCR 
products: Gibson assembly and bacterial transformation are equally 
effective when using unpurified PCR products)
Gibson assembly 1 well
NEBuilder 2X MasterMix 5 µl
Linearized heavy, kappa, or lambda vector 25 ng
Cloning PCR product 1 µl
H2O to 10 µl
2. Incubate the reaction in a thermocycler at 50°C for 1 hr. The 
assembled product can be stored at −20°C before transformation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
a, Comparison of cloning efficiency (the proportion of sequences with a consensus miniprep 
sequence after one attempt) for old and new protocols; each data point represents a separate 
plate. b, ELISA vaccine binding data for 115 influenza vaccine-induced IgG and IgA 
monoclonal antibodies, grouped by subtype and subject ID. c, ELISA vaccine binding data 
for 231 pneumococcal vaccine-induced IgG monoclonal antibodies, grouped by subject ID.
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Figure 2. 
PCR amplification efficiency for various murine cell types, expressed as the percentage of 
wells that have a successfully amplified heavy and light chain; each data point represents a 
plate.
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Figure 3. 
Schematic for cloning antibody genes into expression vectors. PCR with gene-specific 
overhang primers frames the antibody gene on both sides with approximately 20–25 bp of 
overlap with the expression vector. Gibson assembly is then used to join the two fragments.
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Table 1
Comparison of the bench time required to perform the steps in the protocol.
Smith, Nature Methods,
2009
Step New protocol
Unchanged Blood draw and flow cytometry Unchanged
Unchanged cDNA prep Unchanged (RNA bead
purification: add 45
minutes/plate)
Unchanged PCR Unchanged
1 day, 100 sequences Prepare expression vector 15 minutes, 96 sequences
1 hour, 24 sequences Transformation 1 hour, 96 sequences
Unchanged Plasmid DNA preparation Unchanged
Unchanged Cell culture and transfection Unchanged
1 day, 24 antibodies Antibody purification 45 minutes, 24 antibodies
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